Clinical Trials

70 enrolled

Multiple Myeloma

NCT06948084 2026-03-18

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

80 enrolled

Multiple Myeloma

NCT04133636 2026-03-17

CARTITUDE-2

210 enrolled

Multiple Myeloma

NCT06353022 2026-03-17

IFm2022-01

103 enrolled

Multiple Myeloma

NCT06577025 2026-03-13

aMMbition

43 enrolled

Multiple Myeloma

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

33 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05896228 2026-03-11

Iber-KDd

30 enrolled

Multiple Myeloma

NCT03477539 2026-03-09

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

49 enrolled 15 charts

Multiple Myeloma

NCT06083922 2026-03-06

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

20 enrolled

Multiple Myeloma

NCT04656951 2026-03-05

GMMG-DADA

67 enrolled

Multiple Myeloma

NCT07029776 2026-03-03

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

50 enrolled

Multiple Myeloma

NCT03589222 2026-02-27

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

62 enrolled

Multiple Myeloma

NCT04933539 2026-02-27

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

14 enrolled

Multiple Myeloma

NCT06348147 2026-02-17

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Phase 2 Suspended

39 enrolled

Multiple Myeloma

NCT04113018 2026-02-03

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

39 enrolled 16 charts

Multiple Myeloma

NCT05497804 2026-02-03

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

17 enrolled

Multiple Myeloma

NCT06974786 2026-01-23

FASTER

100 enrolled

Multiple Myeloma

NCT05898646 2026-01-13

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

96 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT07335887 2026-01-13

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

39 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT05231629 2026-01-09

MASTER-2

300 enrolled

Multiple Myeloma

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

40 enrolled

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT05695508 2025-12-24

HD10/DSMMXX

160 enrolled

Multiple Myeloma

NCT04009109 2025-12-18

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

79 enrolled

Multiple Myeloma

NCT06827860 2025-12-18

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

23 enrolled

Multiple Myeloma, Recurrence

NCT03290950 2025-12-15

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

75 enrolled

Multiple Myeloma

NCT03346135 2025-12-05

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

31 enrolled

Multiple Myeloma

NCT07110844 2025-11-19

Teclistamab-Daratumumab in AL Amyloidosis

25 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT03763162 2025-10-24

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

40 enrolled

Multiple Myeloma

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

43 enrolled

Multiple Myeloma, Recurrence

NCT03500445 2025-10-03

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

75 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05572229 2025-09-17

IFM2021-01

74 enrolled

Multiple Myeloma

NCT04497961 2025-09-11

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

95 enrolled

Multiple Myeloma

NCT03004287 2025-09-10

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

50 enrolled

Multiple Myeloma

NCT01415882 2025-09-05

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

165 enrolled 15 charts

Multiple Myeloma

NCT07107529 2025-08-12

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

150 enrolled

Multiple Myeloma

NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

401 enrolled

Disease, Multiple Myeloma

NCT04124497 2025-08-08

DPd

45 enrolled

Chromosome 17 deletion, Multiple Myeloma

NCT04635189 2025-08-08

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

28 enrolled

Multiple Myeloma

NCT04052880 2025-07-20

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

17 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04775550 2025-07-02

PRISM

61 enrolled

Multiple Myeloma

NCT01946477 2025-06-06

POM MM 014

186 enrolled

Multiple Myeloma, Neoplasms, Plasmacytoma

NCT03012880 2025-06-04

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

80 enrolled 12 charts

Multiple Myeloma

NCT03490344 2025-05-25

Short Course Daratumumab in Patients With Multiple Myeloma

10 enrolled 8 charts

Multiple Myeloma

NCT04892446 2025-05-02

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

36 enrolled 17 charts

Multiple Myeloma

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

265 enrolled 21 charts 3 FDA

Multiple Myeloma

NCT03556332 2025-04-29

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

41 enrolled

Multiple Myeloma

NCT02316106 2025-04-27

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

123 enrolled

Smoldering Multiple Myeloma, Multiple Myeloma

NCT06931704 2025-04-23

IFM 2024_06

176 enrolled

Multiple Myeloma

NCT04166565 2025-04-17

EMN19

41 enrolled

Multiple Myeloma

NCT03236428 2025-03-05

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

42 enrolled